Stakeholders ask for flexibility, more examples in FDA guidance on overall survival in cancer trials
Stakeholders asked the US Food and Drug Administration for more examples in comments on a recently issued guidance on the use of overall survival as an endpoint in oncology drug clinical trials. They ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results